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ABSTRACT 
Diabetes, which is characterized by elevated plasma glucose, can have a devastating 
effect on peripheral nerves frequently leading to the clinical symptoms of neuropathy. Diabetic 
autonomic neuropathy (DAN) results from damage to autonomic nerves, and the most troubling 
forms of DAN often lead to cardiovascular abnormalities and premature death. Despite the 
prevalence of DAN and the impact to quality and life expectancy, the precise mechanisms 
underlying these pathologies are poorly understood. Recently, a new model for the onset of DAN 
was proposed where hyperglycemia-induced oxidative stress inactivates nicotinic acetylcholine 
receptors (nAChRs), the main receptor driving autonomic synaptic transmission at sympathetic 
ganglia. This inactivation leads to the depression of synaptic transmission, and consequently 
triggers the onset of autonomic neuropathy in diabetic mice. However, the source and pathways 
contributing to the elevation of reactive oxygen species (ROS) and oxidative stress remained 
unclear. 
 In recent years it has been shown that the accelerated formation of advanced glycation 
end products (AGEs) and activation of their receptor (RAGE) in diabetes play a major role in the 
induction of oxidative stress in sensory nerve damage. Thus, we hypothesized that the activation 
and up-regulation of RAGE during high glucose conditions is a major source of ROS production 
in sympathetic neurons leading to the inactivation of nAChRs and autonomic malfunction. In this 
thesis we show for the first time that RAGE is expressed in cultured sympathetic neurons and is 
also up-regulated during high glucose conditions. Our results further demonstrate that direct 
RAGE activation by its natural ligands leads to an increase in cytoplasmic ROS which in turn 
induces the inactivation of nAChRs in sympathetic neurons. We also report that high glucose-
induced ROS generation and subsequent inactivation of nAChRs is prevented in sympathetic 
neurons from RAGE knock-out mice. The results of this dissertation suggest RAGE to be a 
iii 
 
pivotal source of ROS production leading to the functional deficits observed in sympathetic 
neurons during high glucose conditions.
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CHAPTER 1 
 
Diabetes mellitus is characterized for causing elevations in plasma glucose resulting from 
an inadequate production of insulin (type 1) or insulin resistance (type 2). Currently in North 
America, 19 million people live with diabetes mellitus and of those, approximately 90-95% 
suffer from the type 2 form. Diabetes is considered an epidemic in developed countries and it is 
predicted by 2025 that there will be over 300 million people living with this disease (World 
Health Organization). A common characteristic of diabetes is high blood sugar, or 
hyperglycemia, and this leads to a range of neurological complications that worsen with 
duration. Hyperglycemia-induced nerve damage, clinically referred to as diabetic neuropathy, is 
the most common diabetic complication affecting nearly 70% of patients (American Diabetes 
Association; http://www.diabetes.org/diabetes-basics/diabetes-statistics/?loc=DropDownDB-
stats). Sensory and autonomic dysfunction are two common symptoms observed in patients with 
diabetic neuropathy. Diabetic sensory neuropathy is the result of hyperglycemia-induced damage 
to sensory nerves, usually in the arms and legs, leading to abnormal sensory function. This can 
lead to serious complications such as sensory loss, incapacitating pain, foot ulceration, gangrene, 
and infection (Boulton et al., 2004). This often leads to lower leg amputations as over half the leg 
amputations last year in the USA were diabetes related (Fernyhough et al., 2010). People with 
diabetes also often suffer from complications of the autonomic nervous system (ANS), clinically 
called diabetic autonomic neuropathy (DAN), resulting in conditions such as cardiac 
arrhythmias, orthostatic hypotension, gastrointestinal abnormalities, ocular deficiencies, and 
urinary tract problems (Duby et al., 2004; Vinik and Zeigler, 2007). Despite the prevalence of 
DAN and the impact it has on the lives of those affected, it still remains one of the least 
understood and studied complications associated with diabetes (Vinik et al., 2001, 2003). 
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Extensive research has described the structural and biochemical alterations that occur in 
peripheral nerves as a result of diabetes (Schmidt, 2002; Tomlinson & Gardiner, 2008). 
However, the exact sequence of events – from hyperglycemia to the occurrence and progression 
of symptoms typical of clinical neuropathy – has not yet been elucidated. It is the goal of this 
thesis to shed light on the molecular pathways that underlie the pathogenesis of diabetic 
autonomic complications.    
 
1.1Autonomic Nervous System 
1.1.1 General Overview 
The major function of the ANS is to maintain organ system homeostasis. The ANS plays 
a crucial role in maintaining system homeostasis by signaling through a network of neurons that 
works predominately without voluntary or conscious control. Accordingly, the name ‘autonomic’ 
comes from the Greek word autonomia meaning ‘self-governing’ (Richerson, 2009).  The ANS 
is responsible for the innervation and control of all tissues and organs in the body, except skeletal 
muscle, which is governed by the somatic motor system (Bear et al., 2007). Among the tissues 
targeted by the ANS are smooth muscle, cardiac muscle, secretory epithelia and gland cells. 
Examples of ANS function include modulating pupil diameter, dilation and constriction of blood 
vessels, cardiac output, heart rate, and maintaining normal body temperature (Richerson, 2009). 
In addition, autonomic output can be regulated centrally by a distributed network of nuclei 
contained mainly in the hypothalamus and brain stem (Bear et al., 2007).  
 
1.1.2 Function of the ANS 
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The ANS is comprised of three divisions: sympathetic, parasympathetic, and enteric 
(Richerson, 2009). The sympathetic and parasympathetic divisions are the major efferent 
pathways of the ANS and often produce opposite physiological outcomes. For example, the 
sympathetic nervous system controls the “fight-or-flight” response, which is an adaptive reaction 
to harmful or dangerous stimuli. The surge in sympathetic output causes an increase in heart rate, 
cardiac output, respiration, pupil dilation, gluconeogenesis, perspiration, and an increase in blood 
flow to the heart and muscles (Tortora and Derrickson, 2009). Thus, the fight-or-flight response 
primes the body to respond to emotional or physical stress in a fashion that enhances the 
organism’s survival chances. Conversely, the parasympathetic nervous system is often referred 
to as the “rest-and-digest” division due to its function to replenish energy stores and aid in 
digestion (Tortora and Derrickson, 2009). Both sympathetic and parasympathetic divisions 
innervate most organ systems simultaneously and while they can function independent of one 
another, they generally work cooperatively to maintain homeostasis (Richerson, 2009).  
 
1.1.3 Organization and anatomy of the ANS 
All three divisions of the ANS have marked differences in their organization and 
anatomy. The sympathetic and parasympathetic divisions arise from preganglionic neurons, 
whose cell bodies are located in the spinal cord and brain stem of the central nervous system 
(CNS; Bear et al., 2007). These preganglionic neurons send myelinated axons to postganglionic 
neurons organized in autonomic ganglia outside the CNS, which in turn send unmyelinated 
axons to the target organs (Richerson, 2009). In contrast, the organization of the enteric division 
is more diffuse comprising a neuronal network that regulates gastrointestinal homeostasis. 
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In the sympathetic division, the preganglionic fibers originate from the first thoracic 
segment (T1) to the third lumbar segment (L3) of the human spinal cord. These preganglionic 
fibers leave the ventral roots of the spinal cord to form synapses with postganglionic neurons 
housed in sympathetic ganglia (Horn and Swanson, 2013). The human body usually houses 25 
pairs of sympathetic ganglia that are located on either side of the vertebral column (Atri et al., 
2012). The most rostral ganglia in the chain, and the one used in this thesis, is the superior 
cervical ganglion (SCG) which results from the fusion of cervical ganglia C1-C4 (Atri et al., 
2012). It sends its postganglionic fibers to the head and face and innervates the pupil, salivary 
glands, lacrimal glands, sweat glands, and blood vessels. The SCG also provides sympathetic 
innervation to the cerebral vasculature (Horn and Swanson, 2013). The variety of functions 
modulated by the SCG as well as its easy accessibility has facilitated its characterization in 
multiple animal models and thus makes it an excellent model to study sympathetic function.  
In contrast to the sympathetic ganglia, most parasympathetic ganglia lie within or near 
the organ they innervate, and as a result, their axonal fibers are shorter compared to the 
sympathetic fibers. Parasympathetic preganglionic fibers arise from neuronal cell bodies housed 
in the brain stem and sacral segments of the spinal cord, and are often very long since 
parasympathetic ganglia are not close to the spinal cord like the sympathetic ganglia. An 
example of a major parasympathetic tract is the 10
th
 cranial nerve, which is also known as the 
vagus nerve. The vagus nerve provides parasympathetic innervation to major organs such as the 
heart, lungs, kidneys, and gastrointestinal system (Richerson, 2009).  
The enteric division has a more diffuse organization when compared to the sympathetic 
and parasympathetic divisions. The enteric division is a complex interconnected system of 
sensory neurons, interneurons, and autonomic neurons that surrounds and controls the 
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gastrointestinal system (Bear et al., 2007). It is the most complicated division of the ANS and is 
estimated to have as many as 100 million neurons in humans (Horn and Swanson, 2013). The 
enteric division is controlled by two major networks of interconnected neurons: the myenteric 
plexus and the submucous plexus. These two networks work together to control both the 
transport and digestion of food (Bear et al., 2007). In addition, sympathetic and parasympathetic 
innervation of the enteric nervous system can also modulate its activity; however, basic enteric 
functions are still maintained when all innervation to the CNS is removed (Bayliss et al., 1899; 
Furness, 2012).  
 
1.1.4 Synaptic Physiology of the ANS  
Preganglionic neurons of both the sympathetic and parasympathetic nervous system 
release the same primary neurotransmitter, acetylcholine (ACh), to the postganglionic neurons. 
ACh binds to ionotropic nicotinic acetylcholine receptors (nAChRs), located on postganglionic 
autonomic neurons, triggering the flow of mostly sodium and potassium ions (a small increase in 
calcium permeability also occurs). The immediate result is a net inward current that produces a 
fast excitatory postsynaptic potential (EPSP) that is capable of triggering action potential firing 
(Bear et al., 2007). This is the primary mode of neurotransmission in autonomic ganglia. 
However, ACh is also able to activate other receptors expressed on the postganglionic autonomic 
neurons that can modulate the EPSP generated by nAChRs. Activation of M1 muscarinic 
receptors by ACh, which are G protein-coupled receptors that activate second messenger 
cascades to carry out a response, results in a slow EPSP that can last for several seconds. 
Conversely, activation of the dopaminergic receptors by dopamine or the α-adrenergic receptors 
by norepinephrine produces a slow inhibitory postsynaptic potential (IPSP). This membrane 
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hyperpolarization is thought to occur by ACh activation of the M2 muscarinic receptor. Lastly, 
peptides such as angiotensin and substance P that are co-released with ACh can cause a 
depolarization lasting for several minutes called the late, slow EPSP (Atri et al., 2012). In 
summary, fast EPSPs mediated by nAChRs drive autonomic synaptic transmission while the 
other three types of synaptic signals modulate the efficiency of this communication. 
 While all preganglionic autonomic neurons release ACh to drive synaptic transmission, 
postganglionic sympathetic and parasympathetic neurons use different neurotransmitters and 
receptors to drive the activity of their target cell. Sympathetic postganglionic neurons generally 
release norepinephrine which acts on adrenergic receptors. The two main types of adrenergic 
receptors are α and β which can bind both norepinephrine and epinephrine. On the other hand, 
postganglionic parasympathetic neurons are considered cholinergic because they use ACh as 
their primary neurotransmitter. Parasympathetic release of ACh on their target cells induces a 
response by activating muscarinic receptors (Tortora and Derrickson, 2009).  
 
1.2 Nicotinic acetylcholine receptors in autonomic ganglia 
The nAChRs are ligand-gated ion channels (ionotropic receptors) that are members of the 
pentameric Cys-loop receptor family (Richerson, 2009), characterized by a highly conserved pair 
of cysteine residues that forms the ligand binding pocket (Leonard and Bertrand, 2001; 
Albuquerque et al., 2009). Together with the nAChRs, this family also includes serotoninergic 
type 3, glycine, and GABAA receptors. The binding of two ACh molecules to the nAChR results 
in the opening of a non-selective cation pore with strong inward rectification (Dani and Bertrand, 
2007; Atri et al., 2012; Krishnaswamy and Cooper, 2012).  The nAChRs are known to drive fast 
synaptic transmission in autonomic ganglia (David et al., 2010). 
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Five of the eleven neuronal nAChR subunit genes identified so far are found to be 
expressed in mouse sympathetic ganglia : α3, α5, α7, β2, and β4 (Mandelzys et al., 1994; De 
Koninck and Cooper, 1995). In the SCG, nAChRs can occur as homo-pentamers (made up of 
only the α7 subunit) or hetero-pentamers (can contain the α3, α5, β2, and β4 subunits). The 
hetero-pentameric receptors can form with a variety of different subunit combinations, each with 
different functional properties (Mandelzys et al., 1995; McGehee and Role, 1995; Corringer et 
al., 2000, Putz et al., 2008). The most prevalent nAChR in all sympathetic ganglia is the one 
comprised of the α3/β4 subunit combination (Covernton et al., 1994; Lewis et al., 1997; Skok et 
al., 2002).  
Since nAChRs are essential for normal sympathetic function, disruption in the 
functioning of this ion channel often leads to autonomic impairments. For example, patients with 
autoimmune autonomic ganglionopathies (AAG) develop antibodies against the α3 containing 
nAChRs and consequently suffer from severe autonomic complications (Vernino et al., 2008). 
These complications result in common symptoms associated with autonomic failure such as 
orthostatic hypotension, abnormal thermoregulation, gastroparesis, and decreased lacrimation. 
Interestingly, these dysautonomias occur without compromising the structural integrity of the 
ganglia as they remain anatomically intact and are without any signs of degeneration (Vernino et 
al., 2004, 2008, 2009). 
The critical role of nAChRs in autonomic function was also explored in the context of 
diabetes. Recent studies show that accumulation of reactive oxygen species (ROS), which occur 
in diabetes, target intracellular cysteine residues in α3-containing nAChRs expressed in 
sympathetic neurons from the SCG (Campanucci et al., 2008; 2010). This results in the 
depression of sympathetic synaptic transmission and the occurrence of symptoms typical of 
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sympathetic failure (e.g. abnormalities in heart rate and thermoregulation; Campanucci et al., 
2010). The sympathetic problems occurring both in AAG and in diabetes are examples of 
dysautonomias that can be attributed to dysfunctional α3 – containing nAChRs rather than 
general structural deteriorations. These examples show that nAChRs are vital for the proper 
functioning of the ANS.  
 
1.3 Diabetic Autonomic Neuropathy  
1.3.1 Clinical symptoms and treatments 
DAN is a major complication of diabetes leading to nerve dysfunction of the ANS. The 
main risk factors for DAN are hyperglycemia, long duration of diabetes, increasing age, female 
sex, and having a higher body mass index (Vinik and Erbas, 2001). DAN can affect any area of 
the ANS and thus is considered a system-wide disorder affecting many organ systems throughout 
the body. Typical symptoms associated with DAN include resting tachycardia, exercise 
intolerance, orthostatic hypotension, constipation, gastroparesis, erectile dysfunction, and 
impaired neurovascular function (Vinik et al., 2003). Cardiovascular problems are among the 
most troubling autonomic complications as it causes abnormalities in heart rate as well as in 
central and peripheral vascular dynamics. This often is a leading source of morbidity and 
mortality in diabetic patients predisposing them to malignant arrythmogenesis and to sudden 
cardiac death (Vinik and Erbas, 2001).  
Autonomic neuropathy is one of the most common complications arising from diabetes 
with some clinical studies reporting a prevalence rate as high as 100% (Ziegler et al., 1992). 
Many major clinical symptoms do not manifest until after many years with diabetes but when 
they do arise, 25% to 50% of the patients die within 5 to 10 years of diagnosis (Ewing et al., 
 9 
 
1991; Rathmann et al., 1993). Subclinical symptoms of DAN can often be detected within 1 year 
of the onset of type 2 diabetes and within 2 years of type 1 diabetes (Pfeifer et al., 1984). DAN 
significantly increases the chance for mortality as patients are three times more likely to pass 
away within five years of diagnosis compared to diabetic patients without autonomic neuropathy 
(O’Brian et al., 1991).  
The best option to date for treatment of DAN is preventive measures such as intense 
glycemic control, diet, and exercise (Vink et al., 2003). The Diabetes Control and Complication 
Trial Research Group (DCCT Research Group, 1998) showed that tight glycemic control could 
prevent or slow autonomic dysfunction over time in patients with type 1 diabetes. An interesting 
new drug to treat autonomic neuropathy that has recently been approved to be prescribed to 
patients is the antioxidant α-lipoic acid. Early therapy with this antioxidant has shown to slow or 
even reverse the progression of autonomic dysfunction (Ziegler et al, 1999). Other antioxidants 
such as vitamin E have also been shown to improve autonomic function in those with type 2 
diabetes (Manzella et al., 2001). β-blockers and aldose reductase inhibitors seem to also show 
positive results in mitigating the detrimental effects diabetes has on autonomic function (Vinik et 
al., 2003). There are many different drugs on the market to treat DAN and the specific organ 
affected however, as mentioned above, preventive measures and lifestyle changes has shown to 
trump most pharmacological interventions. Also, since the development of DAN is such a 
multifactorial process, a combination of treatments should be further explored.  
1.3.2 Diabetic autonomic neuropathy and sympathetic ganglia 
Evidence from both animal and human studies point that a common neuropathological 
consequence of DAN in most autonomic ganglia is dendritic and axonal pathology without the 
occurrence of much neuronal loss (Schmidt, 2002). The distal portion of axons, especially those 
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of longer length, are commonly found to have undergone degenerative or dystrophic changes 
(Schmidt, 2002; Vinik et al., 2003). Interestingly however, these anatomical changes seem to be 
selective for only certain autonomic ganglia. For example, the superior mesenteric (SMG) and 
celiac ganglia (CG) often develop these anatomical alterations while the SCG seems to be 
spared. The findings observed in human diabetic tissue also seem to correspond well with that of 
experimental animal studies. In the rat model of type 1 diabetes in which streptozotocin (STZ) is 
used to selectively destroy insulin secreting pancreatic cells, a loss of neurons in sympathetic 
ganglia is not observed even after 10 months (Schmidt, 2001). Also consistent with observations 
in human tissue, rodent models of diabetes show neuroaxonal dystrophy in the SMG and CG 
however, this is not observed in the SCG (Schmidt and Plurad, 1986). Why anatomical 
alterations are not observed in the SCG during diabetic conditions is not known.   
 
1.3.3 Pathogenesis of Diabetic Autonomic Neuropathy 
Despite the prevalence of DAN and its detrimental effect on the patient, it is one of the 
least understood and recognized disorders of diabetes. Evidence for detrimental metabolic 
pathways contributing to nerve damage (Greene et al., 1988; Hoeldtke et al., 2002; Vinik et al., 
2001), neurovascular insufficiency (Cameron et al., 1997; Low et al., 1997), abnormal axonal 
transport (Tomlinson, 1983), excessive immune response (Pittenger et al., 1999), and a reduction 
or increase in neurotrophic growth factors (Apfel et al., 1994) have all been linked and attempted 
to explain the etiology of diabetic neuropathy (Vinik et al., 2003). While several hypotheses exist 
explaining the pathogenesis of peripheral nerve damage in diabetes, a single unifying mechanism 
has not been put forth and accepted. For example, one hypothesis is that all autonomic 
complication in diabetes is a result of the diminished blood flow due to microvascular 
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abnormalities (Schmidt, 2002).  This diminished blood flow is thought to result in neuronal 
ischemia and trigger degenerative processes for autonomic neurons. However, this global 
explanation for the pathogenic mechanisms of DAN is confounded by the fact that certain 
autonomic ganglia in diabetes, like the SCG, do not show any signs of structural degeneration 
(Schmidt et al., 1993; Schmidt, 1996). It is likely that diabetes causes neuronal dysfunction 
through different mechanisms depending on neuronal phenotype. 
 
1.4 Four main molecular mechanisms of how hyperglycemia induces cellular damage 
Glucose neurotoxicity is a serious consequence of diabetes and often leads to diabetic 
neuropathies. In order to function properly, neurons demand a high amount of glucose. But 
unlike muscle and fat cells, where glucose uptake is carried by the insulin-dependent GLUT4 
transporter, in neurons glucose uptake is mostly mediated by the insulin-independent GLUT1 
transporter. Thus, glucose transport into neurons follows the glucose concentration gradient and 
insulin regulated glucose transport into brain cells has not yet been shown to occur. This makes 
neuronal cells especially vulnerable to damage via hyperglycemia leading to diabetic neuropathy. 
These neuropathies are especially prevalent in the peripheral nervous system where the neurons 
are not protected from elevated glucose levels by the blood-brain barrier (Tomlinson and 
Gardiner, 2008). 
 In diabetes, intracellular glucose levels are increased fourfold triggering four main 
pathophysiological mechanisms leading to nerve damage (Brownlee, 2001; Tomlinson and 
Gardiner, 2008). These are: increased polyol pathway flux; increased advanced glycation end 
products (AGEs) formation; activation of protein kinase C (PKC) isoforms; and increased 
hexosamine pathway flux.  These four pathways are linked together by a single hyperglycemia-
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induced process: oxidative stress by the overproduction of reactive oxygen species (Brownlee, 
2001).  
 
1. Increased activation of polyol (sorbitol) pathway 
In normal euglycemic conditions, such as in non-diabetic people, most of the glucose in 
peripheral nerves is phosphorylated by hexokinase and enters into the glycolytic pathway as 
glucose-6-phosphate. However, in diabetes, high blood glucose saturates hexokinase resulting in 
glucose to be diverted into the polyol pathway (van Heyningen et al., 1959; Gabbay et al., 1966). 
The first enzyme in this pathway, aldose reductase, reduces glucose to sorbitol by consuming 
NADPH. In hyperglycemia, a significant amount of sorbitol accumulates intracellularly and is 
not cleared due to its low plasma membrane permeability. Several mechanisms have been 
proposed to explain how hyperglycemia-induced increases in polyol pathway flux contribute to 
glucose neurotoxicity. These include osmotic stress caused by intracellular sorbitol 
accumulation, decreased (Na
+ 
- K
+
) ATPase activity, an increase in cytosolic nicotinamide 
adenine dinucleotide (NADH/NAD
+
), and finally decreases in cytosolic NADPH (Brownlee, 
2001; Tomlinson & Gardiner, 2008). Activation of the polyol pathway may also indirectly 
damage neurons by decreasing nerve blood flow (Greene et al., 1988).   
 
 
2. Increased activation of protein kinase C  
Intracellular hyperglycemia increases diacylglycerol concentration which ultimately 
activates protein kinase C (PKC; Koya et al., 1998). PKC activation is also thought to be 
indirectly mediated by RAGE-ligand interaction (Portilla et al., 2000) and the increased flux of 
glucose through the polyol pathway (Keogh et al., 1997). Studies have shown that abnormal 
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PKC activation is involved in several of the mechanisms thought to underlie diabetic 
neuropathies. This includes the reduced formation of nitric oxide and the increased production of 
endothelin-1 which contributes to vasoconstriction (Ishii et al., 1996). Consequently, this leads to 
reduced nerve blood flow, a characteristic commonly seen in diabetic patients (Cameron et al., 
1997). PKC activation also increases vascular permeability, promotes angiogenesis, and induces 
a pro-inflammatory response (Brownlee, 2001; Tomlinson & Gardiner, 2008).  
 
3. Increased flux through the hexosamine pathway 
In hyperglycemic conditions, fructose-6-phosphate from glycolysis is diverted into the 
hexosamine pathway. Eventually, fructose-6-phosphate is converted into uridine diphosphate-N-
acetylhexosamine (UDP-GlcNAc) which is known to bind to serine and threonine residues on 
intracellular proteins. This interaction between UDP-GlcNAc and serine and threonine is known 
to cause protein dysfunction and also promotes gene transcription factors, such as specificity 
protein 1 (Sp1), which are involved in causing hyperglycemia-induced neuronal damage 
(Brownlee, 2001; Tomlinson & Gardiner, 2008).   
 
4. Increased AGE formation  
AGEs are mostly formed by the non-enzymatic glycation of proteins, lipids, and 
nucleotides (Lee and Cerami, 1989; Brownlee, 2000). Increased AGE accumulation is a normal 
process of aging but AGE production is accelerated under hyperglycemic conditions (Brownlee, 
2000; Ulrich and Cerami, 2001; Thornalley, 2002). Current research attributes a major role of 
AGEs in the pathogenesis of neurological complications caused by diabetes. AGE levels are 
proportional to the duration of diabetes and often excessive amounts lead to oxidative stress, 
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inappropriate transcription signals, interruption of cellular pathways, and inflammatory-like 
neuronal damage. AGE buildup also leads to protein cross-linking and aggregation both intra- 
and extracellularly (King, 2001; Thornalley, 2002; Wang et al., 2003; Layton and Sastry, 2004). 
In addition to the direct structural effects of AGE, there is interaction of AGE with cell surface 
receptors. Many of these receptors bind and destroy AGEs while others, like the receptor for 
AGEs (RAGE), mediate key intracellular signaling processes (Neeper et al., 1992; Schmidt et al., 
1996; Singh et al., 2001; Thornalley, 2002). RAGE is the main receptor for AGE-mediated 
signaling and has been implicated in several diabetic complications including atherosclerosis, 
retinopathy, nephropathy, and neuropathy. RAGE activation is also thought to significantly 
contribute to oxidative stress in hyperglycemic conditions (Huang et al., 2001; Wautier et al., 
2001; Zill et al., 2001; Singh et al., 2001; Ishihara et al., 2003;  Xu and Kyriakis, 2003; Shaw et 
al., 2003; Zill et al., 2003; Li et al., 2004; Toth et al., 2007). A more detailed discussion of 
RAGE will be discussed in section 1.6. 
   AGEs can be formed via three main ways: intracellular auto-oxidation of glucose to 
glyoxal; slow, spontaneous rearrangement of the Amadori product to 3-deoxyglucosone; and 
conversion of the products of glycolysis, glyceraldehyde-3-phosphate and dihydroxyacetone, to 
the highly reactive methyglyoxal (Brownlee, 2001). These reactive dicarbonyls – glyoxal, 
deoxyglucosone, and 3-deoxyglucosone – mainly react with the amino group of extracellular and 
intracellular proteins to form AGEs (Yamagishi et al., 2008). There is substantial evidence 
implicating the accumulation of AGEs as a critical biochemical event underlying the 
development of diabetic neuropathies. These observations are supported by both animal and 
clinical research that shows that the AGE formation inhibitor aminoguanidine partially prevents 
nerve damage associated with diabetes (Brownlee, 2001).  
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 Abnormal AGE accumulation has been found to exist in both the central and peripheral 
nervous system under hyperglycemic conditions (Toth, 2007). A study by Misur et al. (2004) 
found that AGEs were highly expressed on the axons and myelin sheaths of diabetic peripheral 
nerves and the amount of AGE expression was proportional with the severity of morphological 
alterations. AGE-related modifications of proteins in peripheral nerves can lead to dysfunction of 
several cellular proteins such as tubulin, neurofilament, and (Na
+ 
+ K
+
) ATPase (Toth, 2007). It 
has also been reported that AGE modifications of proteins impaired myelin synthesis in 
peripheral nerve, which may correlate with the thinning of myelin noticed in mouse models that 
develop diabetic neuropathy (Misur et al., 2004).  
 
1.5 Role of oxidative stress in diabetic neuropathy 
All four mechanisms that contribute to glucose neurotoxicity – increased flux through the 
polyol and hexosamine parthways, PKC activation, and AGE formation – are linked together by 
their tendency to increase oxidative stress in response to high glucose. These findings suggest 
oxidative stress as a common mechanism underlying the pathogenesis of diabetic neuropathy. 
Hyperglycemia overloads glucose metabolic pathways resulting in increased free radical 
generation and oxidative stress. If the free radical production exceeds the antioxidant capacity of 
a cellular system, oxidative stress occurs. Excessive free radical accumulation results in the 
damage of proteins, lipids, and nucleic acids by oxidative stress (Brownlee, 2001). Accumulation 
of such injury impairs biological activity of the cell and often leads to apoptotic cell death 
(Vincent et al., 2004).   
Superoxide (O2
-
), hydrogen peroxide (H2O2), and superhydroxide (OH) are three of the 
most common oxygen free radicals, or reactive oxygen species (ROS), which accumulate in 
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response to hyperglycemic insult and causes oxidative stress. In high glucose conditions, the 
mitochondrial electron transport chain overproduces superoxide. Usually in normal metabolic 
conditions, superoxide is converted into the powerful oxidizer, hydrogen peroxide, and then 
enzymatically cleared via transformation into water by catalase. However, in hyperglycemia, 
increased glucose flux through the polyol pathway impairs this clearance mechanism and results 
in the accumulation of hydrogen peroxide. This in turn causes the increased production and 
accumulation of superhydroxide by way of the Fenton reaction (Brownlee, 2001; Tomlinson and 
Gardiner, 2008).  
  Hyperglycemia-induced oxidative stress is the most accepted hypothesis to explain the 
development of diabetic neuropathy. Studies have found that this oxidative stress triggers 
apoptotic mechanisms in sensory neurons and supporting glial cells and could be a unifying 
mechanisms leading to diabetic neuropathy (Vincent et al., 2004). More recently, it was also 
reported that oxidative stress plays a major role disrupting sympathetic function and triggering 
symptoms of DAN in diabetic mice (Campanucci et al., 2010) 
Most people with diabetes develop complications of the ANS that adversely affect their 
quality of life and life expectancy. DAN causes cardiac arrhythmias, orthostatic hypotension and 
gastrointestinal abnormalities (Duby et al., 2004; Vinik and Zeigler, 2007). Yet, the cause of 
many of these diabetes induced complications are poorly understood. It was recently reported 
(Campanucci et al., 2010) that synaptic transmission in sympathetic ganglia was depressed in 
diabetic mice. To understand the mechanism behind this finding, the authors concentrated on 
nAChRs, the main receptor driving autonomic synaptic transmission, in cultured sympathetic 
neurons during diabetic conditions. Neurons that were exposed to high glucose conditions in 
vitro showed a use-dependent inactivation of nAChRs mediated by oxidative stress. This 
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inactivation was found to cause depression of autonomic synaptic transmission in sympathetic 
ganglia, which in turn led to the decrease in sympathetic drive in various animal models of 
diabetes. Moreover, the onset of autonomic neuropathy was prevented by manipulating the level 
of oxidative stress with the help of antioxidants or by genetically mutating nAChRs subunits, 
making these receptors insensitive to oxidation. Thus, hyperglycemia-induced oxidative stress 
inactivates nAChRs, which depresses autonomic function and triggers the onset of diabetic 
autonomic neuropathy. Through this research, it is now clear that hyperglycemia produces an 
accumulation of ROS in sympathetic neurons, however; the major mechanism underlying ROS 
generation has not yet been documented (Campanucci et al., 2008, 2010).  
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Figure 1-1. Effect of ROS on sympathetic synaptic transmission. (A) During sustained 
hyperglycemia, glucose-generated free radicals (O2
–
) oxidize cysteine residues in the α subunit 
(red) of the nAChR through which they diminish sympathetic synaptic transmission and trigger 
consequent alterations in peripheral tissue function. Glucose-generated ROS may arise from 
within SCG neurons via substrate oxidation or from extracellular sources. (B) Mutating the α 
subunit of the nAChR (yellow) by eliminating cysteine residues prevents free-radical-induced 
impairment of nAChR signaling allowing continued synaptic transmission despite 
hyperglycemia-induced free-radical generation (modified with permission from Diano and 
Horvath, 2010). 
 
 
 
 
 
 
A 
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1.6 RAGE  
RAGE is a multi-ligand receptor of the immunoglobulin family expressed in both the 
central and peripheral nervous systems (Toth et al., 2007). Under physiological conditions, 
RAGE plays a role in development, neuronal growth and survival, tissue repair, and the 
elimination of AGE-modified compounds (Vlassara, 2001; Rong et al., 2005). In contrast, it has 
also been implicated in various disease states such as diabetes, tumor outgrowth, chronic 
inflammation, and several neurodegenerative disorders such as Alzheimer’s disease, stroke, and 
multiple sclerosis (Toth et al., 2007; Vincent et al., 2007). RAGE is composed of three 
extracellular domains, a single transmembrane domain, and a short cytoplasmic tail necessary for 
signaling (Fig. 1-2, Leclerc et al., 2009). RAGE interacts with several ligands such as the 
S100/calgranulin family, high-mobility group box 1 (HMGB1), amyloid-beta peptide, and 
AGEs. RAGE ligands are often released during cellular or physiological stress and interaction 
with RAGE often leads to the viscous inflammatory-related cycle of RAGE activation, up-
regulation, and further activation (Toth et al., 2007; Vincent et al., 2007; Sims et al., 2010). 
A considerable amount of evidence suggests that the interaction of RAGE with its ligands 
initiates signal transduction cascades involved in a variety of diabetic complications, including 
atherosclerosis, retinopathy, nephropathy, and neuropathy (Ritthaler et al., 1995; Hudson et al., 
2003;  Sakaguchi et al., 2003, Wendt et al., 2003; Flyvbjerg et al., 2004). One particular 
consequence of RAGE signaling that is the intense focus of current research is the production of 
ROS. RAGE ligands are significantly increased in diabetes and it has been proposed that 
activation of RAGE signaling pathways produce ROS, likely via nicotinamide adenine 
dinucleotide phosphate (reduced; NADPH) oxidase, which in turn results in further RAGE 
ligand formation and RAGE up-regulation (Yan et al., 2004). This enhancement of RAGE 
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signaling is at the center of current research aiming to understand the mechanisms of nervous 
system damage in diabetes. 
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Figure 1-2. Schematic representation of RAGE and its ligands. The extracellular domain 
(ED) comprises three immunoglobulin-like domains: the V, C1 and C2 domain.  A single 
transmembrane helix connects the extracellular domain with the short intracellular domain (ID).  
RAGE ligands interact with the extracellular domains as indicated (obtained with permission 
from Leclerc et al., 2009).   
 
 
 
 
 
 
 
 
 
 
 ED 
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1.7 Objectives  
The main objective of this thesis is to identify a major source of ROS production in 
cultured sympathetic neurons exposed to high glucose. We anticipate that if such a source is 
detected and blocked, the pro-oxidative signaling that has been shown to cause nAChR 
inactivation in sympathetic neurons will be diminished. This in turn should prevent the 
autonomic synaptic depression and consequent autonomic dysfunction observed in diabetic mice. 
Specifically, we hypothesize that RAGE signaling is the major contributor to high glucose 
induced ROS production in SCG neurons. In this thesis I test this hypothesis using 
electrophysiological, imaging, and biochemical techniques in vitro. The main goal of this study 
is to shed light on novel therapeutic approaches for the treatment and prevention of autonomic 
dysfunction caused by diabetes.  
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CHAPTER 2 
MATERIALS AND METHODS 
Neuronal primary cultures. All experiments were approved by the University of 
Saskatchewan’s Animal Research Ethics Board, and adhered to the Canadian Council on Animal 
Care guidelines for humane animal use. SCG neurons were cultured from neonatal (P1-P3) C57 
black 6 (C57BL6) wild-type or RAGE knock-out (RAGE KO) mice as previously described 
(Campanucci et al., 2008). Briefly, mice were euthanized by cervical transection in a sterile 
environment and SCGs were removed. Ganglia were placed in a Petri dish with serum-
containing media (L15 supplemented with vitamins, cofactors, penicillin-streptomycin, 5 mM 
glucose, and 10% horse serum). Once cleaned, the ganglia were enzymatically dissociated at 
37°C in Hanks balanced salt solution (HBSS) containing trypsin (180–200 U/ml; Worthington, 
Freehold, NJ, USA) and buffered with HEPES (adjusted to pH 7.4 with NaOH). The resulting 
cell suspension was washed twice in serum-containing medium, to inactivate the trypsin, and 
plated on laminin-coated coverslips attached to modified 35 mm tissue culture dishes. Neurons 
were grown in media consisting of L-15 supplemented with vitamins, cofactors, penicillin–
streptomycin, 5 mM glucose, 5% rat serum and NGF (10 ng/ml). Cultures were maintained at 37 
°C in a humidified atmosphere of 95 % air-5 % CO2 and fed every 3-4 days with growth media. 
To eliminate non-neuronal cells, cultures were treated with cytosine arabinoside (10 μM; Sigma, 
St. Louis, MO, USA) from days 2 to 4.   
 
Culture conditions and treatments. After a waiting period of 1 week to allow recovery from 
stress and axotomy due to culturing procedures, neurons were either maintained in control 
conditions (5 mM glucose) or were switched to experimental treatments for an additional week. 
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To mimic hyperglycemic insult, cultures were treated with high glucose (HG)-containing growth 
media (25 mM glucose). In some experiments neurons were exposed to RAGE ligands, such as 
S100 protein (5-15 µg/ml; EMD Biosciences, San Diego, CA), HMGB-1 protein (1-5 µg/ml; 
Sigma), or AGE-BSA (200-300 µg/ml, BioVision). To block RAGE function during high 
glucose insult, a polyclonal antibody against RAGE (anti-RAGE) designed to block its function 
was used (30 μg/ml). For antioxidant treatment, 100 μM of the antioxidant α-lipoic acid and 
1000 U/ml of catalase were prepared fresh on the day of the experiment and applied through the 
patch pipette during whole-cell recording.  
 
Whole-cell recording. ACh-evoked currents were measured using whole-cell patch-clamp 
techniques. Membrane currents were recorded with an Axopatch 200B amplifier and a Digidata 
1440A digitizer (Molecular Devices, Union City, CA). Series resistance compensation was not 
employed during data recording. Recordings were conducted at room temperature, sampled at 5 
kHz, and stored on a personal computer. Recording electrodes had resistances of 5-12 MΩ and 
the cell membrane potential was clamped at -60 mV. pClamp 10.2 software (Molecular Devices) 
was used for data acquisition and analyses. Recording electrodes were filled with the following 
solution (in mM): 65 KF, 55 KAc, 5 NaCl, 0.2 CaCl2, 1 MgCl2, 10 EGTA, 2 MgATP, and 10 
HEPES, and pH was adjusted to 7.2 with KOH. Cultured neurons were perfused with control 
extracellular solution containing (in mM): 140 NaCl, 5.4 KCl, 0.33 NaH2PO4, 0.44 KH2PO4 , 2.8 
CaCl2, 0.18 MgCl2, 10 HEPES, 5 glucose, 2 glutamine, and 5 μg/ml phenol red; pH was adjusted 
to 7.4 NaOH. ACh (100 μM) was dissolved in the perfusion solution and was applied under 
gravity using a perfusion fast-step system (SF-77B, Warner Instruments). Neurons were exposed 
repeatedly to 1 second applications of ACh-containing perfusion solution every 15 seconds. TTX 
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(1 μM; Alomone Labs Ltd., Jerusalem, Israel) was added to the perfusion solution to block 
action potential generation during ACh applications. To quantify the run-down of the ACh-
evoked currents we plotted the ratio of the peak current (I) in response to the 90
th
 application 
(I90) in a series to the peak current in response to the 1st application (I1) in the series.  
 
Intracellular ROS measurements. To quantify the changes in cytosolic ROS we used the ROS-
sensitive dye CM-H2DCFDA (Molecular Probes, Burlington, Ontario, Canada) as previously 
described (Campanucci et al., 2008; 2010). Cultures were incubated for 45 min at 37°C with 
medium containing CM-H2DCFDA (10 μM) and subsequently washed three times with control 
perfusion solution (see above). The cultures were then placed on the stage of an inverted 
microscope (AxioObserver; Carl Zeiss, Germany) and viewed through a 40x (1.3 numerical 
aperture) oil-immersion objectives (Zeiss) at room temperature. To obtain fluorescent images, 
we excited the cultures with 470 nm wavelength using a Colibri 2.0 LED illumination system 
(Zeiss) and collected 510-550 nm wavelength emissions with an AxioCam camera (Zeiss) 
controlled by AxioVision software (Zeiss). LED intensity and exposure times were kept the same 
for all neurons imaged. To quantify the fluorescent intensity, the difference in the intensity of the 
region of interest (neuronal cell body excluding the nucleus) from the background was taken.  
 
Immunocytochemistry. To measure RAGE or protein adducts of 4-hydroxyl-2-nonenal (HNE), 
we fixed neurons with 4% paraformaldehyde for 1 hour at room temperature (Campanucci et al., 
2003). After washing 3 times with PBS (3 minutes each wash), the cells were then blocked with 
10% horse serum for 30 minutes. Cultured neurons were then incubated overnight at 4°C with a 
rabbit anti-RAGE (1:1000, Chemicon, Temecula, CA) or 4-HNE antibody (1:500, Alpha 
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Diagnostics Intl., San Antonio, TX) diluted in PBS containing 1% BSA and 0.5% Triton X-100. 
The next day, the samples were washed in PBS (three times for 3 minutes each) and then 
incubated in the dark for 1 hour at room temperature with a goat anti-rabbit secondary antibody 
conjugated to FITC (1:500; Invitrogen). Samples were covered with an anti-photobleaching 
reagent (Vectashield; Vector Laboratories, Burlingame, CA) and viewed with an epifluorescence 
microscope as described above. Fluorescence intensity was analyzed by subtracting the region of 
interest from background. 
  
Western Blotting. SCG neurons exposed to control or high glucose conditions were lysed using 
a 1% NP-40 lysis buffer containing various protease inhibitors. Protein concentration was 
determined by Bradford assay and samples were resolved by 10% SDS-PAGE and then 
electrotransferred onto a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). The 
resulting membrane was incubated with the following primary antibodies overnight at 4°C: 
rabbit anti-RAGE (1:1000; Chemicon), rabbit anti-NFкB (1:1000; Santa Cruz Biotechnology, 
Santa Cruz, CA) and mouse anti-GAPDH (1:10,000; Abcam, Cambridge, MA). The membrane 
was then washed three times with TBST (20 mM Tris, 150 mM NaCl, 0.1% Tween 20) before 
being probed with either a horseradish peroxidase-conjugated goat anti-rabbit or mouse 
secondary antibody (1:20000; Bio-Rad Laboratories). Protein signals were visualized using 
enhanced chemiluminescence reagents (Santa Cruz Biotechnology) and quantified by performing 
densitometry using ImageJ software (NIH, Bethesda, MD). 
 
Statistics. All statistical analyses were done using Graphpad InStat 3.0. All values are reported 
as mean±s.e.m. and p values less than or equal to 0.05 were considered statistically significant. 
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For comparisons of the increase in RAGE immunofluorescence and RAGE/GAPDH ratio 
between control and high glucose groups, we used the Mann-Whitney U test. To determine the 
statistical differences between the I90/I1 ratios, where appropriate, either the Mann-Whitney U 
test or Kruskal-Wallis Test followed by post hoc comparisons using the Dunn’s Multiple 
Comparisons test was employed. Statistical comparison between control and S100 treatment for 
mean CMH2-DCFDA and HNE fluorescent intensities were determined using the Mann-Whitney 
U test. For comparisons between control and HG conditions for mean CMH2-DCFDA and HNE 
fluorescent intensities, the nonparametric Kruskal Wallis Test was used followed by Dunn’s post 
hoc analysis.    
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CHAPTER 3 
RESULTS 
3.1 SCG neurons show increased expression of RAGE in high glucose conditions. 
Previous reports on sensory neurons show that RAGE protein is expressed at low levels 
in control conditions and is up-regulated when exposed to high glucose conditions (Vincent et 
al., 2007). Since RAGE activation is associated with the generation of ROS, here we propose 
that RAGE expression in sympathetic neurons is up-regulated during high glucose conditions 
and is a major source of ROS production contributing to nAChR inactivation. To test this, RAGE 
expression was observed and quantified by immunofluorescence. Recent findings from our 
laboratory (Chang and Campanucci, unpublished observations) show that cultured sympathetic 
neurons from the SCG were found to express a basal level of RAGE in control conditions that 
appeared broadly distributed over the soma and processes. Exposure to high glucose (from 24 hrs 
up to 8 days) caused a significant increase (p<0.05) in RAGE immunofluorescence (RAGE-IF), 
which plateaued by 48 hours and remained elevated for the length (8 days) of the experiment 
(Fig. 3.1A). Exposure to high glucose for 6 (not shown) to 12 hours had no effect on the level of 
RAGE expression (p>0.05). These data were further supported by the detection of a significant 
increase in the level of RAGE protein after 1 week of high glucose treatment using Western 
Blotting (Fig. 3.1B). A single RAGE band was observed at approximately 50 kDa and high 
glucose (0.55±0.16) treatment resulted in more than a 4 fold increase in RAGE expression 
relative to GAPDH when compared to control (0.13 ±0.01).   
 
3.2 The RAGE ligand S100 increases oxidative stress markers in SCG neurons. 
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Reports from several different cell types, including sensory neurons (Vincent et al., 
2007), endothelial cells (Brownlee, 2000) smooth muscle cells, and mononuclear phagocytes 
(Stern et al., 2002), have shown that RAGE activation directly leads to oxidative stress. To 
confirm this in cultured SCG neurons, we activated RAGE by exposing the cells to the natural 
RAGE ligand S100 protein (15 μg/ml) for 1 week. Working concentration for S100 was 
determined using electrophysiological experiments (see section 3.3D). Increase in cytoplasmic 
ROS levels and protein adducts of 4-hydroxy-2-nonenal (HNE), a major by-product of 
endogenous lipid peroxidation, are common markers for cellular oxidative stress (Halliwell and 
Whiteman, 2004; Eruslanov and Kusmartsev, 2010). Thus, we quantified the cell’s oxidative 
state by monitoring cytoplasmic ROS levels by CM-H2DCFDA fluorescence or HNE 
immunofluorescence. As expected, exposure to S100 protein caused a significant increase in 
both DCFDA (Control: 1545±50 AU; S100: 3587±73 AU) and HNE (Control: 4182±76 AU; 
S100: 4610 ± 66 AU) levels quantified as an increase in fluorescent intensity (Fig. 3.2). These 
results suggest that activation of RAGE leads to pro-oxidative signaling in SCG neurons.  
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 3.1: SCG neurons show increased expression of RAGE in high glucose conditions. 
(A) Fluorescent images of RAGE immunostained SCG neurons exposed to control and high 
glucose conditions for 12 hrs and up to 8 days. Exposure of these neurons to high glucose 
resulted in a time-dependent increase in RAGE immunofluorescence (RAGE-IF). The line graph 
summarizes in arbitrary units the change in RAGE–IF measured as the difference in mean pixel 
intensity compared to control. The increase in RAGE-IF was significantly different by 24 hrs and 
plateaued by 2 days in high glucose (p<0.001). In contrast, neurons exposed to 12 hrs of high 
glucose or kept in control conditions did not show any significant change in RAGE-IF. The scale 
bar represents 50 µm. Findings are the work of Christine Chang. (B) Representative 
immunoblots showing RAGE protein expression in control and high glucose conditions in 
cultured SCG neurons. The bar graph shows the average integrated densities of the RAGE band 
normalized to that of GAPDH for neurons cultured in control (n=4) or in high glucose (n=4) 
conditions. Each point in (A) and bar in (B) represents the mean ± s.e.m.; *p<0.05. 
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Figure 3.2: The RAGE ligand S100 increases oxidative stress markers in SCG neurons.  
(A) Fluorescent images of neurons cultured in control conditions or incubated with S100 protein  
(15 μg/ml) for 1 week and loaded with CM-H2DCFDA or immunostained for protein adducts of  
HNE. The scale bar is 50 µm. (B) The bar graphs show the average fluorescence intensity in  
arbitrary units for neurons cultured in control (n=348 neurons from 3 dishes) or in the presence  
of S100 protein (n=540 neurons from 3 dishes) for ROS detection with DCFDA (left) or HNE  
immunofluorescence respectively (right; n= 100 neurons from 3 dishes for each bar). Each bar 
 represents the mean ± s.e.m.; ***p<0.001.  
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3.3 RAGE ligands induce oxidation-mediated inactivation of nAChRs in SCG neurons.  
Previous studies have shown that cytoplasmic ROS accumulation induces the inactivation 
of nAChRs in SCG neurons, which results in autonomic dysfunction (Campanucci et al., 2008, 
2010). Given that direct activation of RAGE by S100 protein induces ROS accumulation, the 
question arose whether direct RAGE activation also induces the use-dependent inactivation of 
nAChRs in cultured SCG neurons. To explore this possibility we exposed cultured SCG neurons 
to increasing concentrations of the natural RAGE ligands S100 and HMGB1 proteins and 
determined that 15 µg/ml and 5µg/ml, respectively, significantly induced the run-down of ACh-
evoked currents (Fig. 3.3A). The effects of 1 week exposure to S100 (15 μg/ml; (I90/I1: 0.64 
±0.07) or HMGB1 (5 μg/ml; I90/I1: 0.51 ±0.05) are summarized in figure 3.3 (B&C). We also 
wanted to determine if exposure to BSA-AGEs, the most studied RAGE ligand contributing to a 
myriad of diabetic complications (Goh and Cooper, 2008), induces the inactivation of nAChRs. 
As expected, exposing SCG neurons for 1 week to 300 μg/ml of BSA-AGE, the approximate 
amount found in diabetic tissue (One et al., 1998), resulted in nAChR inactivation (I90/I1: 0.87 
±0.04; Fig. 3.3D). These results indicate that induction of RAGE function by its ligands causes 
nAChR inactivation in SCG neurons.  
Next, since antioxidant treatment successfully prevented the oxidation-mediated 
inactivation of nAChRs in SCG neurons (Campanucci et al., 2010), we concentrated on the 
potential beneficial role of antioxidants to treat the RAGE-mediated effects. Thus, to determine 
whether the RAGE-mediated inactivation of nAChR is indeed caused by cytoplasmic ROS, we 
co-exposed sympathetic neurons to S100 protein and to the antioxidants α-lipoic acid (100 μM) 
and catalase (1000 units/ml) for 1 week. The antioxidant mix successfully prevented the 
inactivation of nAChR currents induced by the S100 treatment (S100+AO I90/I1: 0.96±0.07; Fig. 
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3.3B). These data further supports the role of RAGE as a major source of cytoplasmic ROS 
during high glucose conditions. 
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A                                                            B 
Figure 3.3: Activation of RAGE signaling induces nAChR inactivation and this effect is 
prevented by antioxidant treatment. (A) Each point represents the mean I90/I1 ± s.e.m for SCG 
neurons exposed to various concentrations of S100 or HMGB1. The points are fitted using an 
exponential decay function (S100: r
2
=0.93; HMGB1: r
2
=0.96). ** refers to p < 0.01.  (B) 
Currents evoked by a series of ACh (100 μM) applications on SCG neurons from wild-type mice 
in control conditions, incubated for 1 week with 15 μg/ml S100, control conditions and 
intracellularly perfused with an antioxidant mix (α-lipoic acid and catalase), or 1 week 
incubation with 15 μg/ml S100 protein and intracellularly perfused with the antioxidant mix. To 
help visualize the effect of the treatments on ACh-evoked currents, only one every ten traces are 
shown. Histogram summarizes the ratio of the 90
th
 ACh-evoked current to the first in the series 
(I90/I1) for SCG neurons incubated for 1 week in control (n=7), S100 (n=12), control plus 
antioxidants (n= 6), and S100 plus antioxidants (n=8). Each bar is the mean I90/I1 ± s.e.m; ** 
refers to p < 0.01. (C) Similar experiment as in (A) but comparing the effect of incubating 
cultured SCG neurons from wild type mice in media containing HMGB1 (5 μg/ml; n = 7) for 1 
week versus control (n = 5). Each bar is the mean I90/I1 ± s.e.m; ** refers to p < 0.01.(D) Similar 
experiments as in (A) and (B) but in this case comparing the effect of incubating cultured SCG 
neurons from wild type mice in media containing BSA-AGEs (300 μg/ml; n = 13) for 1 week 
versus control (n = 10). Each bar in (B), (C) and (D) is the mean I90/I1 ± s.e.m; ** refers to p < 
0.01. The n values reported in (B), (C) and (D) were obtained from 3-6 dishes for each condition.  
0.5 nA 
15 s 
C D 
** 
** 
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3.4 High glucose induced inactivation of nAChRs is prevented in SCG neurons with 
disrupted RAGE signaling. 
A recent report has shown that high glucose heightens the oxidative state of SCG neurons 
which results in nAChR inactivation (Campanucci et al., 2010). As shown above, high glucose 
induced the up-regulation of RAGE and RAGE activation increased oxidative markers in 
sympathetic neurons and caused nAChR inactivation. Thus, in order to determine whether 
RAGE plays a role in causing nAChR inactivation under high glucose, we used a RAGE 
neutralizing antibody to disrupt RAGE signaling. Exposure to 30 μg/ml of the RAGE 
neutralizing antibody blocks approximately 50% of RAGE radio-ligand binding (R & D 
Systems). This is consistent with unpublished observations from a collaborator (Dr. Fernyhough 
at the University of Manitoba) who shows that 30 μg/ml of antibody is sufficient to significantly 
disrupt the RAGE-mediated neurite outgrowth of embryonic sensory neurons in vitro. Our 
results show that when SCG neurons were co-incubated with the RAGE neutralizing antibody 
under high glucose conditions for 1 week, this treatment partially prevented the run-down effects 
of high glucose on ACh-evoked currents (Control I90/I1: 1.05 ± 0.04; HG I90/I1: 0.77 ±0.06; HG + 
Ab I90/I1: 0.92 ±0.05; Fig. 3.4).  
 
3.5 High glucose fails to induce oxidative stress and nAChR inactivation in SCG neurons 
from RAGE KO mice. 
The findings shown so far strongly suggest that RAGE signaling has a pivotal role in the 
generation of oxidative stress and inactivation of nAChRs in SCG neurons exposed to high 
glucose conditions. Therefore, to confirm this possibility we took advantage of mice that lack 
exon 1 in the RAGE gene, resulting in global RAGE knock-out (RAGE KO) (Myint et al., 2006). 
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Our results indicate that high glucose induced-ROS formation (Control: 1486±36 AU; HG: 
2089±65 AU) and lipid peroxidation (Control: 4050±53 AU; HG: 4837±63 AU) was prevented 
in SCG neurons from RAGE KO mice (ROS: 1089±32 AU; HNE 4152±84 AU; Fig. 3.5) 
suggesting that RAGE is required for the deleterious effects of high glucose. Interestingly, we 
observed that basal cytoplasmic ROS measured as CM-H2DCFDA fluorescence levels was 
significantly lower in SCG neurons from RAGE KO mice (1032±20 AU) than from wild-type 
mice (1486±36 AU) maintained in the same control (5 mM glucose) media (Fig. 3.5A).  These 
results suggest that RAGE signaling may contribute to the basal redox state of autonomic 
neurons. 
Using RAGE KO mice we also confirmed that RAGE is required to impair nicotinic 
function under high glucose conditions. When SCG neurons cultured from RAGE KO mice were 
exposed to high glucose for 1 week, they showed stable ACh-evoked currents (HG I90/I1: 1.00 
±0.08) suggesting that high glucose failed to induce nAChR inactivation (Fig. 3.6). Passive 
membrane properties (membrane potential, Vm; membrane capacitance, Cm; and access 
resistance, Ra) were not significantly different in wild type and RAGE KO neurons exposed to 
both control and high glucose conditions (Table 3.1). We also incubated SCG neurons from 
RAGE KO mice for 1 week with S100 protein (15 μg/ml), HMGB1 (5 μg/ml) or AGEs (300 
μg/ml), and in all these cases, ACh-evoked currents were not significantly affected (S100 I90/I1: 
1.03 ± 0.11; HMGB1 I90/I1: 0.81 ±0.08; AGEs I90/I1: 1.02 ± 0.03; Fig. 3.6). However, although 
not statistically significant, HMGB1 was still able to cause some decline of ACh-mediated 
currents. This effect could be explained by the known pro-oxidative signaling of HMGB1 
through its other binding sites, such as toll-like receptors (Gill et al., 2010).  
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Figure 3.4: High glucose induced inactivation of nAChRs is prevented by a RAGE function 
blocking antibody. (A) Currents evoked by ACh (100 μM) applications on SCG neurons from 
wild type mice maintained in control glucose concentration, 1 week in high glucose (HG), or 1 
week in high glucose plus anti-RAGE antibody (30 μg/ml). After the first trace, every tenth trace 
is shown for clarity. (B) Histogram summarizes the ratio of the 90
th
 ACh-evoked current to the 
first in the series (I90/I1) for SCG neurons incubated for 1 week in control glucose concentration 
(n=10 neurons from 4 dishes), high glucose (n=14 neurons from 7 dishes), and high glucose plus 
anti-RAGE antibody (n=11 from 5 dishes). Each bar is the mean I90/I1 ± s.e.m; ** refers to p < 
0.01. 
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Figure 3.5: High glucose fails to induce ROS accumulation and HNE-protein adduct 
formation in SCG neurons from RAGE KO mice. (A) Fluorescent images of ROS detection 
in SCG neurons from wild-type and RAGE KO mice maintained in either control or high glucose 
conditions for 1 week. The bar graph shows the average DCFDA fluorescence intensity in 
arbitrary units for neurons from wild-type mice in control (n=129) or high glucose (n=140) 
conditions, and neurons from RAGE KO mice in control (n=118) or high glucose (n=119) 
conditions. Data was collected from 3 dishes for each condition. (B) Immunofluorescent images 
for HNE protein adducts in SCG neurons from wild-type and RAGE KO mice maintained in 
either control or high glucose conditions for 1 week. The bar graph shows the average 
fluorescence intensity for HNE in arbitrary units for neurons from wild-type and RAGE KO 
mice in control or high glucose conditions (n= 100 neurons from 3 dishes for each bar). Each bar 
in (A) and (B) represents the mean ± s.e.m.; ***p<0.001. The scale bar in (A) and (B) is 50 µm 
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Figure 3.6: Sympathetic neurons lacking RAGE do not show nAChR inactivation when 
incubated with high glucose or RAGE ligands. (A) Currents evoked by a series of ACh (100 
μM) applications on SCG neurons from RAGE KO mice maintained in either control conditions 
or incubated for 1 week with high glucose, 15 μg/ml S100 protein, 5 μg/mL HMGB1, or 300 
μg/mL BSA-AGEs. After the first trace, every tenth trace is shown for clarity. (B) Histogram 
summarizes the ratio of the 90
th
 ACh-evoked current to the first in the series (I90/I1) for RAGE 
KO SCG neurons maintained in either control conditions (n=6) or incubated for 1 week with 
high glucose (n=11), 15 μg/ml S100 protein (n=7), 5 μg/mL HMGB1 (n=7), or 300 μg/mL BSA-
AGEs (n=8). Data was collected from 3-5 dishes for each condition. Each bar is the mean I90/I1 ± 
s.e.m.     
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 Wild-type RAGE KO 
 5 mM 25 mM 5 mM 25 mM 
Vm (mV) -38.25±2.9 -40.31±2.27 -49.5±2.53 -44.5±3.82 
Cm (pF) 25.56±2.71 27.49±2.30 34.84±4.16 23.9±2.25 
Ra (MΩ) 32.4±2.78 29.72±2.28 28.95±1.87 32.98±3.14 
 
Table 3.1: Passive membrane properties. Comparison of mean passive membrane properties 
for cultured SCG neurons from wild type and RAGE KO mice exposed to both, control (5 mM) 
and high glucose (25 mM) conditions. Note, mean values were not significantly different. N 
values are the same as those reported above for the respective ACh-evoked current recording.  
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CHAPTER 4 
DISCUSSION 
In this study we use an in vitro approach to highlight RAGE as a major source of high 
glucose-triggered oxidative stress leading to sympathetic neuron dysfunction. Recently, a new 
model for the onset of dysautonomia in diabetes was proposed where hyperglycemia-induced 
oxidative stress inactivates nicotinic acetylcholine receptors (nAChRs), the main receptor driving 
autonomic synaptic transmission in sympathetic ganglia. This inactivation leads to the depression 
of synaptic transmission, and consequently triggers the onset of autonomic neuropathy in 
diabetic mice (Campanucci et al., 2010). However, the source and pathways contributing to the 
elevation of ROS and generation of oxidative stress remained unclear. We show here that RAGE 
protein levels are up-regulated in high glucose conditions and that ligand activation of RAGE 
increases cellular oxidative stress leading to nAChR inactivation in cultured sympathetic 
neurons. We then go on to report that in the absence of RAGE expression, using RAGE KO 
mice, the accumulation of ROS and subsequent inactivation of nAChRs that occurs in high 
glucose conditions were prevented. These results shed light on RAGE as a major source of ROS 
production in hyperglycemic conditions and suggest a pivotal role of RAGE in the development 
of diabetic autonomic neuropathy.  
 
RAGE protein expression is up-regulated in high glucose conditions  
Several studies have previously reported the detrimental effects of RAGE up-regulation 
and activation in contributing to both vascular and renal dysfunction observed in diabetes 
(Yamamoto et al., 2000; Stern et al., 2002). However, very few studies have looked at the 
involvement of RAGE expression and signaling in diabetic neuropathy. In DRG neurons, which 
are affected in diabetic sensory neuropathy, exposure to RAGE ligands caused an increase in 
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RAGE expression and activation resulting in severe oxidative stress and neuronal apoptosis 
(Vincent et al., 2007). It was observed in mouse models of long-term diabetes an increased 
RAGE expression in neurons and especially in Schwann cells (Toth et al., 2007). Patients with 
diabetic sensory neuropathy have also been reported to have increased RAGE and NF-кB 
activation in peripheral nerves (Bierhaus et al., 2004). This increased expression corresponds 
with the observation that RAGE blockade in animal models prevented the majority of sensory 
deficits caused by diabetes (Bierhaus et al., 2004). While the above work has examined the 
contribution of RAGE towards the sensory abnormalities observed in diabetes, the purpose of 
this thesis was to investigate whether RAGE plays a similar pathological role in autonomic 
neurons exposed to diabetic conditions.  
Here we show for the first time by immunocytochemistry (Chang and Campanucci, 
unpublished observations) and western blotting that RAGE is expressed in cultured sympathetic 
neurons and is up-regulated by high glucose in a progressive, time-dependent fashion (Fig. 3.1). 
However, we do not know the molecular mechanisms mediating this increase in RAGE 
expression. RAGE signaling often leads to sustained activation of NF-кB, a pro-inflammatory 
transcription factor (Yan et al., 1994; Bierhaus et al., 2004), suggesting that the deleterious 
effects of RAGE are linked to inflammation. Interestingly, the RAGE promoter contains binding 
sites for NF-кB, allowing NF-кB activity levels to have a positive feed-back effect on RAGE 
expression (Li and Schmidt, 1997). This may explain why RAGE up-regulation and signaling 
often produces a vicious inflammatory cycle where activation leads to further RAGE up-
regulation. This RAGE-mediated chronic inflammatory cycle has been observed in sensory 
neurons (Feldman et al., 2007), vascular endothelial and carcinoma cells (Li and Schmidt, 1997; 
Stern et al., 2002). However, these reports contrast with our preliminary findings which do not 
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show changes in phosphorylation of NF-кB (data not included) in our cultured sympathetic 
neurons exposed to high glucose. It is possible that RAGE is being up-regulated by another 
transcription factor such as specificity protein 1 (SP-1), which also binds to the RAGE promoter 
independently from NFкB (Li and Schmidt, 1997). Also, even though increased NF-кB activity 
is observed with long-term diabetes in both human and animal models (Bierhaus et al., 2001), rat 
models with diabetes for a moderate amount of time has shown diminished NF-кB activity 
(Purves and Tomlinson, 2002). Therefore, it is possible that exposing SCG neurons to high 
glucose for 1 week was too short of a period for an observable NF-кB increase. Further 
experiments will be required to clarify this observation.  
 
Ligand activation of RAGE causes oxidative stress and nAChR inactivation  
In this thesis it was demonstrated that exposure of SCG neurons to the natural RAGE 
ligand S100 causes an increase in oxidative stress (Fig. 3.2). This is in agreement with several 
studies in a multitude of cell types showing that ROS production and accumulation is a common 
downstream effect of sustained RAGE activation (Yan et al., 1994; Lander et al., 1997; Wautier 
et al., 2001; Xu et al., 2003; Ding et al., 2007 Vincent et al., 2007). A previous study has shown 
that elevations in cytosolic ROS induced nAChRs inactivation leading to synaptic depression in 
intact sympathetic ganglia (Campanucci et al., 2008). Thus, as we expected, SCG neurons 
exposed to three natural RAGE ligands (S100, HMGB1, and AGEs) resulted in the inactivation 
of nAChRs. To confirm this was mediated by oxidative stress, we successfully prevented the 
S100-induced nAChR inactivation by co-treating cells with antioxidants. Interestingly, AGEs 
(Brownlee, 1992; Ulrich and Cerami, 2001; Thornalley, 2002), S100 (Kosaki et al., 2004), and 
HMGB1 (Yao and Brownlee, 2009) have been shown to be increased in diabetic tissue and may 
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be one of the main contributors in ROS generation and the subsequent depression of autonomic 
synaptic transmission. Supporting this view are adipocytes, which have also been reported to be 
a major source of S100 secretion. Therefore, adipocyte dysfunction or obesity, which is 
intimately link to type II diabetes, may further add to autonomic dysfunction by excessive S100 
secretion (Steiner et al., 2010).  
Our findings revealing the deleterious effects of RAGE signaling on autonomic function 
could potentially have broader implications for our understanding of both the physiology and 
pathophysiology of the ANS. This is the case for satellite glial cells, which are specialized glial 
cells in autonomic ganglia found tightly wrapped to neurons and responsible for controlling the 
neuronal microenvironment (Hanani, 2005, 2010). Interestingly, satellite glial cells are known to 
highly express S100 proteins (Hanani, 2010), and since these cells may have a major role in 
influencing sympathetic synaptic transmission by controlling the composition of the neuronal 
microenvironment, it is possible that RAGE  plays a role in mediating neuron-glia 
communication. We have shown here that incubating cultured SCG neurons with exogenous 
S100 proteins inactivates nAChRs, most likely acting through RAGE. For future research it 
would be interesting to explore the possibility whether S100 released from satellite glial cells 
contributes to the SCG synaptic depression reported in diabetes (Campanucci et al., 2010). 
However, we should also consider the potential contribution of other sources of S100 proteins 
that could further impact the pro-inflammatory microenvironment generated in diabetes, such as 
astrocytes (Gerlach et al., 2006; Tramontina et al., 2006; Ellis et al., 2007), macrophages (Ellis et 
al., 2007), and Schwann cells (Perrone et al., 2008).  
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Inhibiting RAGE function prevents high-glucose induced oxidative stress and nAChR 
inactivation 
Here we showed that high-glucose failed to induce accumulation of cytoplasm ROS in 
cultured SCG neurons from RAGE KO mice (Fig. 3.5A). Furthermore, cytosolic ROS levels in 
neurons from RAGE KO mice showed a lower basal ROS fluorescence compared to wild-type. 
Therefore, these findings led us to propose that not only is RAGE the predominant source of 
oxidative stress under high glucose conditions in our system but also that it contributes to the 
normal cytoplasmic redox state of autonomic neurons. Another intriguing aspect of how RAGE 
can affect neuronal function under pathological conditions comes from the recent report showing 
RAGE expression in mitochondria in cancer cells (Kang et al., 2013). In cancer cells RAGE has 
pro-survival functions by enhancing mitochondrial activity and ATP production. However, if 
RAGE is indeed expressed in the mitochondria of SCG neurons and if it has any role in 
mitochondrial bioenergetics in either physiological or pathological conditions remains to be 
determined. 
After revealing that RAGE expression was needed for high glucose to induce ROS 
accumulation, our next logical step was to determine if the high glucose mediated nAChR 
inactivation was prevented in neurons where RAGE function was hampered. We show that by 
co-exposing sympathetic neurons to high glucose and a function blocking RAGE antibody, the 
nAChR inactivation was partially prevented (Fig. 3.4). Further, when exposing SCG neurons 
from RAGE KO mice to high glucose, inactivation was completely prevented (Fig. 3.6). As 
expected from the above imaging experiments, nAChRs were insensitive to the effects of high 
glucose in neurons lacking RAGE. This is likely explained by the prevention of ROS generation 
in RAGE KO neurons, thus preserving the normal functioning of nAChRs.  
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A recent study by Campanucci et al. (2010) reported that hyperglycemia causes an 
irreversible inactivation of nAChRs in sympathetic neurons. An important point to note is that 
even though our general conclusions remain consistent with that of the recent study, the 
magnitude and time course of the high glucose-induced inactivation of ACh-evoked currents is 
markedly different. We observed a slow but consistent run-down of approximately 30% by the 
90
th
 ACh-evoked current while the previous report shows a faster and larger decline (70% run-
down by the 30
th
 application; Campanucci et al., 2010). This discrepancy can be accounted for 
by two main factors. First, the perfusion system during whole-cell recording was completely 
different between the two studies. In the previous report, agonist applications were performed 
with the help of a compressed-gas puffer pipette of just 2-5 µm in diameter. The main 
weaknesses of that system were that the final concentration of agonist applied to the cell depends 
on the distance that the puffer pipette is placed from the cell membrane, and that all currents are 
obtained from a small and discrete area of the cell body instead of from the vast dendritic 
arborization characteristic of SCG neurons. To circumvent these issues in the present thesis, 
agonist application was performed using a fast step continuous perfusion system. The fast step 
perfusion system generates a constant river of solution that switches back and forth commanded 
by the patch clamp amplifier and it uses a much larger diameter pipette (0.6 mm) resulting in 
currents evoked from the full cell body and dendrites of cultured neurons. In addition, we cannot 
discard the possibility that the discrepancies in magnitude and time course of the run-down of 
ACh-evoked currents are based on the health of our cultured neurons. The health of neurons in 
cultures that depend on NGF for survival is related to the amount of NGF used. In the current 
study we used 60% less NGF in our culture media than in Campanucci et al. (2010) and neurons 
were maintained healthy for up to 1 month; the current amount of NGF used was markedly 
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apoptotic for the neurons used in the original study (unpublished observations). Thus, it is 
possible that we are observing less nAChR inactivation compared to Campanucci et al. due to the 
fact our neurons are in a healthier state. Overall, we are confident that the discrepancy between 
the studies can be attributed to differences in experimental design instead of biological reasons.  
 
Future Directions:  
Two critical questions still remain unanswered – 1) how is RAGE being activated by high 
glucose in our in vitro experimental set-up; 2) What are the molecular mechanisms that produce 
oxidative stress in response to RAGE activation?  To address the first question, we hypothesize 
that a significant portion of RAGE activation occurs because of the formation of AGEs due to 
high glucose in the culture media. An in vitro study of monocytes has shown that only two hours 
are needed to form AGEs and induce NF-кB signaling in response to hyperglycemia (Schiekofer 
et al., 2003). Thus, incubating sympathetic neurons with high glucose for one week should 
provide more than enough time to form enough AGEs in vitro for a significant increase in RAGE 
activation. Another source of RAGE activation may be the cultured sympathetic neurons 
themselves. Accumulating evidence suggests that S100 and HMGB1 can be secreted in response 
to certain stimuli and then act in an autocrine or paracrine fashion to induce RAGE activation 
(Wang et al., 1999; Schmidt et al., 2000; Scaffidi et al., 2002; Bonaldi et al., 2003; Donato, 2007; 
van Beijnum et al., 2013). Further experiments are needed to determine if high glucose 
stimulates the extracellular secretion of RAGE ligands from sympathetic neurons.  
 To address the second question we must focus on the RAGE downstream signaling 
cascade. The molecular pathways mediating RAGE signaling is an area of intense research that 
could one day have many therapeutic implications. However, there are still many questions 
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remaining about how RAGE is able to incorporate many diverse ligands into so many different 
cellular responses. Evidence suggests that RAGE activation results in the rapid generation of 
ROS by a mechanism that in part involves the activation of NADPH oxidase (Yan et al., 1994; 
Lander et al., 1997; Wautier et al., 2001; Vincent at al., 2007). Other studies have also shown 
RAGE signaling occurring primarily via the MAPK and PI-3K/Akt pathway which eventually 
leads to ROS formations via NADPH oxidase activation (Lander et al., 1997; Ishihara et al., 
2003; Shanmugam et al., 2003; Xu et al., 2003; Zill et al., 2003; Vincent et al., 2007). Future 
experiments need to be designed to address if NADPH oxidase activity is increased in SCG 
neurons exposed to high glucose and if this is prevented in neurons from RAGE KO mice.  
Preliminary evidence from our lab also shows strong increases in PI-3K/Akt signaling pathway 
in SCG neurons exposed to high glucose for 1 week; however, no increase in the MAPK 
pathway was observed (data not shown).   
A future and critical goal of this work is to test whether blocking RAGE function has a 
protective effect in maintaining normal sympathetic function in STZ-induced diabetic mice. 
Using similar measures of sympathetic activity as conducted by Campanucci et al. (2010), we 
plan to study if sympathetic function becomes depressed in STZ-induced diabetic RAGE KO 
mice. The results presented in this thesis strongly support a crucial role of RAGE in the onset 
and development of diabetic autonomic neuropathy. We anticipate that the diabetes induced 
sympathetic dysfunction would be milder or occur later in mice lacking RAGE.  
Another future goal of this project is to propose RAGE as a potential therapeutic target for 
the treatment of DAN. There are currently only two main functionally relevant isoforms of 
RAGE: the full length RAGE in which signaling is achieved by the intracellular tail and the 
soluble isoform (known as sRAGE; Schmidt et al., 2000). The sRAGE isoform lacks the 
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transmembrane domain and can therefore act as a decoy receptor and block RAGE activation 
(Leclerc et al., 2009; Sims et al., 2010). sRAGE may act as a potential therapeutic agent against 
pathologies where there is excessive RAGE activation (Vincent et al., 2010). Interestingly, it has 
been found that plasma sRAGE is decreased in diabetic patients and it may contribute to diabetic 
complications by increasing the availability of RAGE ligands to interact with membrane-bound 
RAGE (Katakami et al., 2005). Thus, we are interested in testing the efficacy of sRAGE in 
treating the autonomic complications caused by diabetes.  Preliminary steps have already been 
taken in order to achieve this goal in collaboration with Dr. Scott Napper by isolating and 
purifying sRAGE from mouse lung tissue using a previously published protocol (Englert et al., 
2008). We anticipate that sRAGE will be helpful in preventing the deterioration of sympathetic 
function in STZ-induced diabetic mice. Previous studies have reported that sRAGE treatment 
was more efficient to ameliorate diabetic complications than the complete deletion of RAGE 
(Bierhaus et al., 2004). This is probably due to the fact that sRAGE prevents RAGE ligands from 
binding to RAGE and also to other binding sites capable of producing cellular dysfunction.  
 
General Conclusions  
The detrimental effects of RAGE activation and the subsequent downstream ROS 
production and accumulation have been shown in the context of diabetic sensory neuropathy. 
However, little is known about the involvement of RAGE in autonomic malfunction during 
hyperglycemia. Here we show in cultured sympathetic neurons that RAGE is expressed in 
control conditions but is up-regulated in response to high glucose. Further, we demonstrate that 
the high glucose induced ROS production and the following nAChR inactivation is prevented in 
sympathetic neurons where RAGE function is blocked. These results portray RAGE as a major 
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source of ROS production in response to high glucose that eventually results in autonomic 
neuron malfunction. We propose that the blockade of RAGE activation offers new therapeutic 
approaches for treating DAN.  
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